Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02HHW
|
|||
Former ID |
DIB019650
|
|||
Drug Name |
CP608,039
|
|||
Synonyms |
CP-608,039
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C23H25ClN8O5
|
|||
Canonical SMILES |
CC1=NOC(=C1)OCC2=C(C=C(C=C2)Cl)CNC3=C4C(=NC=N3)N(C=N4)C5C(C(C(O5)C(=O)NC)N)O
|
|||
InChI |
1S/C23H25ClN8O5/c1-11-5-15(37-31-11)35-8-12-3-4-14(24)6-13(12)7-27-20-17-21(29-9-28-20)32(10-30-17)23-18(33)16(25)19(36-23)22(34)26-2/h3-6,9-10,16,18-19,23,33H,7-8,25H2,1-2H3,(H,26,34)(H,27,28,29)/t16-,18+,19-,23+/m0/s1
|
|||
InChIKey |
KXDJDMIUJGBFAV-QYUDBREXSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Agonist | [2] |
Adenosine A3 receptor (ADORA3) | Target Info | Agonist | [3] | |
KEGG Pathway | cGMP-PKG signaling pathway | |||
cAMP signaling pathway | ||||
Sphingolipid signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
RANKL Signaling Pathway | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Reactome | Adenosine P1 receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | Nucleotide GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
GPCRs, Other | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5598). | |||
REF 2 | Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006 Mar;5(3):247-64. | |||
REF 3 | Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2780-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.